FDA Bars Generic Versions of Painkiller OxyContin

04-16-2013 • Wall Street Journal

The FDA decision extends Purdue Pharma LP's patent protection of OxyContin for at least another year, if not much longer. The blockbuster pain drug racked up sales of $2.8 billion last year. By blocking generic entrants, the FDA will reward companies